Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2001-7-18
pubmed:abstractText
Grubbs' olefin metathesis reaction was utilized to prepare a macrocyclic variant of a linear Grb2 SH2 domain antagonist in an attempt to induce a beta-bend conformation known to be required for high affinity binding. In extracellular Grb2 SH2 domain binding assays, the macrocyclic analogue exhibited an approximate 100-fold enhancement in binding potency relative to its linear counterpart. The macrocycle was not as effective in whole cell binding assays as would be expected based on its extracellular binding potency.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0960-894X
pubmed:author
pubmed:issnType
Print
pubmed:day
23
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1889-92
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11459654-Adaptor Proteins, Signal Transducing, pubmed-meshheading:11459654-Breast Neoplasms, pubmed-meshheading:11459654-Cell Division, pubmed-meshheading:11459654-Cyclization, pubmed-meshheading:11459654-Drug Design, pubmed-meshheading:11459654-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:11459654-GRB2 Adaptor Protein, pubmed-meshheading:11459654-Humans, pubmed-meshheading:11459654-Inhibitory Concentration 50, pubmed-meshheading:11459654-Models, Molecular, pubmed-meshheading:11459654-Molecular Conformation, pubmed-meshheading:11459654-Peptides, pubmed-meshheading:11459654-Protein Binding, pubmed-meshheading:11459654-Proteins, pubmed-meshheading:11459654-Receptors, Drug, pubmed-meshheading:11459654-Signal Transduction, pubmed-meshheading:11459654-Structure-Activity Relationship, pubmed-meshheading:11459654-Tumor Cells, Cultured, pubmed-meshheading:11459654-Tyrosine, pubmed-meshheading:11459654-src Homology Domains
pubmed:year
2001
pubmed:articleTitle
Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor.
pubmed:affiliation
Laboratory of Medicinal Chemistry, Center for Cancer Research, NCI at Frederick, National Institutes of Health, MD 21702, Frederick, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't